Memory Impairment – Pipeline Review, H2 2015

“Memory Impairment – Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Memory Impairment – Pipeline Review, H2 2015’, provides an overview of the Memory Impairment’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Memory Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Memory Impairment and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global therapeutic landscape of Memory Impairment
– The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in the therapeutics development for Memory Impairment and enlists all their major and minor projects
– The report summarizes all the dormant and discontinued pipeline projects
– A review of the Memory Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– A detailed assessment of monotherapy and combination therapy pipeline projects
– Coverage of the Memory Impairment pipeline on the basis of target, MoA, route of administration and molecule type
– Latest news and deals relating related to pipeline products

Reasons to buy

– Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Develop strategic initiatives by understanding the focus areas of leading companies
– Identify and understand important and diverse types of therapeutics under development for Memory Impairment
– Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
– Devise corrective measures for pipeline projects by understanding Memory Impairment pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline”

“Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Memory Impairment Overview 8
Therapeutics Development 9
Pipeline Products for Memory Impairment – Overview 9
Pipeline Products for Memory Impairment – Comparative Analysis 10
Memory Impairment – Therapeutics under Development by Companies 11
Memory Impairment – Therapeutics under Investigation by Universities/Institutes 12
Memory Impairment – Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Memory Impairment – Products under Development by Companies 15
Memory Impairment – Products under Investigation by Universities/Institutes 16
Memory Impairment – Companies Involved in Therapeutics Development 17
AbbVie Inc. 17
Calico LLC 18
M et P Pharma AG 19
Neuren Pharmaceuticals Limited 20
Omeros Corporation 21
Sunovion Pharmaceuticals Inc. 22
Takeda Pharmaceutical Company Limited 23
Memory Impairment – Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
A-988315 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
AC-253 – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Antisense Oligonucleotides to Inhibit microRNA for Neurology – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
dehydroevodiamine hydrochloride – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
HT-0712 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
HT-3951 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
NNZ-2591 – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
P7-C3A20 – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
pregnenolone succinate – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
roflumilast – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecule 1 to Inhibit GlyT-1 for Memory Impairment – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecule 1 to Inhibit PDE4 for Memory Impairment – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecule 2 to Inhibit Glyt-1 for Memory Impairment – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecule 2 to Inhibit PDE4 for Memory Impairment – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Small Molecule to Activate Carbonic Anhydrase for Learning and Memory Impairment – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecule to Activate LPL for CNS and Metabolic Disorders – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecule to Inhibit D-amino acid oxidase for Neuropathic Pain, Inflammatory Pain and Memory Impairment – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecule to Inhibit Glutamate Carboxypeptidase 2 for Cognitive Impairment and Memory Impairment – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Small Molecule to Inhibit MAO-B for Memory Impairment – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Small Molecule to Target GPR83 for CNS and Immunological Disorders – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecules to Activate NAMPT for Neurological Disorders – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Small Molecules to Activate PKC for CNS and Oncology – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Small Molecules to Antagonize GALR3 for Memory Impairment – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Memory Impairment – Recent Pipeline Updates 59
Memory Impairment – Dormant Projects 62
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64″
“List of Tables
Number of Products under Development for Memory Impairment, H2 2015 9
Number of Products under Development for Memory Impairment – Comparative Analysis, H2 2015 10
Number of Products under Development by Companies, H2 2015 11
Number of Products under Investigation by Universities/Institutes, H2 2015 12
Comparative Analysis by Clinical Stage Development, H2 2015 13
Comparative Analysis by Early Stage Development, H2 2015 14
Products under Development by Companies, H2 2015 15
Products under Investigation by Universities/Institutes, H2 2015 16
Memory Impairment – Pipeline by AbbVie Inc., H2 2015 17
Memory Impairment – Pipeline by Calico LLC, H2 2015 18
Memory Impairment – Pipeline by M et P Pharma AG, H2 2015 19
Memory Impairment – Pipeline by Neuren Pharmaceuticals Limited, H2 2015 20
Memory Impairment – Pipeline by Omeros Corporation, H2 2015 21
Memory Impairment – Pipeline by Sunovion Pharmaceuticals Inc., H2 2015 22
Memory Impairment – Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 23
Assessment by Monotherapy Products, H2 2015 24
Number of Products by Stage and Target, H2 2015 26
Number of Products by Stage and Mechanism of Action, H2 2015 28
Number of Products by Stage and Route of Administration, H2 2015 30
Number of Products by Stage and Molecule Type, H2 2015 32
Memory Impairment Therapeutics – Recent Pipeline Updates, H2 2015 59
Memory Impairment – Dormant Projects, H2 2015 62″
“List of Figures
Number of Products under Development for Memory Impairment, H2 2015 9
Number of Products under Development for Memory Impairment – Comparative Analysis, H2 2015 10
Number of Products under Development by Companies, H2 2015 11
Number of Products under Investigation by Universities/Institutes, H2 2015 12
Comparative Analysis by Clinical Stage Development, H2 2015 13
Comparative Analysis by Early Stage Products, H2 2015 14
Assessment by Monotherapy Products, H2 2015 24
Number of Products by Top 10 Targets, H2 2015 25
Number of Products by Stage and Top 10 Targets, H2 2015 25
Number of Products by Top 10 Mechanism of Actions, H2 2015 27
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 27
Number of Products by Top 10 Routes of Administration, H2 2015 29
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 29
Number of Products by Top 10 Molecule Types, H2 2015 31
Number of Products by Stage and Top 10 Molecule Types, H2 2015 31″